natgillin/translations-raw huggingface dataset:
Exposure to telaprevir is higher during co-administration of peginterferon alfa and ribavirin than after administration of telaprevir alone.
Stopnja izpostavljenosti bolnika telaprevirju je večja med sočasnim jemanjem peginterferona alfa in ribavirina kot pa po jemanju samega telaprevirja.
Exposure to temperatures below 2°C will not damage the product providing it is not stored below
Izpostavljenost temperaturam pod 2 °C zdravilu ne bo škodovalo, pod pogojem, da ni shranjeno pri temperaturi pod
Exposure to temperatures below 2°C will not damage the product providing it is not stored below – 20°C.
Izpostavljenost temperaturam pod 2 °C zdravilu ne bo škodovalo, pod pogojem, da ni shranjeno pri temperaturi pod -20 °C.
Exposure to the active substance may elicit an allergic response in susceptible individuals.
Izpostavljenost zdravilni učinkovini lahko pri občutljivih posameznikih izzove alergijsko reakcijo.
Exposure to the active substance may elicit an allergic response in susceptible persons.
Izpostavljenost zdravilni učinkovini lahko pri občutljivih posameznikih izzove alergijsko reakcijo.
Exposure to the other metabolites is less than 5%.
Izpostavljenost drugim presnovkom je manj kot 5 %.
Exposure to these
Pričakovano je zvečanje
Exposure to ticagrelor and the active metabolite were approximately 20% lower in patients with severe renal impairment (creatinine clearance <30 ml/min) compared to subjects with normal renal function (see section 4.2).
Izpostavljenost tikagrelorju in njegovemu aktivnemu presnovku je bila pri bolnikih s hudo okvaro ledvic (očistek kreatinina < 30 ml/min) približno 20 % manjša kot pri osebah z normalnim delovanjem ledvic (glejte poglavje 4.2).
Exposure to ticagrelor was approximately 20% lower and exposure to the active metabolite was approximately 17% higher in patients with severe renal impairment (creatinine clearance
Pri bolnikih s hudo okvaro ledvic (očistek kreatinina < 30 ml/min) je bila izpostavljenost ticagrelorju približno 20 % manjša in izpostavljenost njegovemu aktivnemu presnovku približno
Exposure to vandetanib is not affected by food.
Hrana ne vpliva na izpostavljenost vandetanibu.
exposure to Viramune, caution should be exercised if the medicinal products are given concomitantly and patients should be monitored closely.
Zaradi nevarnosti povečane izpostavljenosti zdravilu Viramune moramo biti pri sočasnem dajanju teh zdravil previdni in bolnike skrbno spremljati.
Exposure-adjusted rates for adverse reactions (all Grades and Grade 3/4) in Study 1, a clinical trial in patients with multiple myeloma comparing Empliciti combined with lenalidomide and dexamethasone treatment (N = 318) to lenalidomide and dexamethasone treatment (N = 317), is shown in Table 4.
Deleži neželenih učinkov, prilagojeni glede na izpostavljenost (vse stopnje in stopnje 3/4) v študiji 1, kliničnem preskušanju, izvedenem pri bolnikih z multiplim mielomom, v katerem so zdravljenje z zdravilom Empliciti v kombinaciji z lenalidomidom in deksametazonom (N = 318) primerjali z zdravljenjem z lenalidomidom in deksametazonom (N = 317), so prikazani v tabeli 4.
exposures
kombinaciji
exposures
paritaprevirju je
Exposures (AUC0-24) of oritavancin in skin blister fluid were 20% of those in plasma after a single 800 mg dose in healthy subjects.
Izpostavljenosti (AUC0-24) oritavancinu v tekočini kožnih mehurjev so bile enake 20 % izpostavljenosti v plazmi po enem 800 mg odmerku pri zdravih prostovoljcih.
Exposures of elvitegravir, cobicistat, emtricitabine, tenofovir, and tenofovir alafenamide achieved in 24 paediatric patients aged 12 to < 18 years who received Genvoya in study GS-US-292-0106 were similar to exposures achieved in treatment-naïve adults following administration of Genvoya (Table 5).
Izpostavljenosti elvitegravirju, kobicistatu, emtricitabinu, tenofovirju in alafenamidtenofoviratu, ki jih je doseglo 24 pediatričnih bolnikov, starih 12 do < 18 let, ki so prejemali zdravilo Genvoya v študiji GS-US-292-0106, so bile podobne izpostavljenostim, doseženim pri predhodno nezdravljenih odraslih po dajanju zdravila Genvoya (preglednica 5).
Exposures of emtricitabine and tenofovir alafenamide given with elvitegravir+cobicistat achieved in 24 paediatric patients aged 12 to < 18 years were similar to exposures achieved in treatment-naïve adults (Table 5).
Izpostavljenosti emtricitabinu in alafenamidtenofoviratu v kombinaciji z elvitegravirom + kobicistatom, ki jih je doseglo 24 pediatričnih bolnikov, starih 12 do < 18 let, so bile podobne izpostavljenostim, doseženim pri predhodno nezdravljenih odraslih (preglednica 5).
Exposures of raltegravir (a UGT1A1 substrate) are reduced in the presence of efavirenz (see section 4.5, table 1).
Izpostavitev raltegravirju (substratu za UGT1A1) se v prisotnosti efavirenza zmanjša (glejte poglavje 4.5, Preglednica 2).
exposures was observed when
Pri jemanju indinavirja
exposures was observed when indinavir
Pri jemanju indinavirja
exposures.
25-O-deacetil-rifabutinu.
Express your breast milk regularly and throw away any breast milk you have expressed.
Mleko si v tem času redno izbrizgavajte in vse iztisnjeno mleko zavrzite.
Extavia 250 microgram (Placebo) n=292 (n=176)
Extavia 250 mikrogramov (Placebo) n=292 (n=176)
Extavia contains 300 microgram (9.6 million IU) of recombinant interferon beta-1b per vial*.
Zdravilo Extavia vsebuje 300 mikrogramov (9,6 milijonov i.e.) rekombinantnega interferona beta-1b na vialo*.
Extavia contains human albumin and therefore carries a potential risk for transmission of viral diseases.
Zdravilo Extavia vsebuje humani albumin, zato obstaja morebitno tveganje za prenos virusnih bolezni.
Extavia contains sodium
Zdravilo Extavia vsebuje natrij
Extavia has also been studied in 1,657 patients in two studies of secondary progressive MS patients who were able to walk, where it was compared with placebo.
Zdravilo Extavia so proučevali tudi v okviru dveh študij pri 1 657 bolnikih s sekundarno progresivno multiplo sklerozo, sposobnih hoje, pri čemer so ga primerjali s placebom.
Extavia is a powder and solvent for solution for injection.
Zdravilo Extavia je prašek in vehikel za raztopino za injiciranje.
Extavia is a powder and solvent that are made up into a solution for injection.
Zdravilo Extavia je prašek in vehikel za pripravo raztopine za injiciranje.
Extavia is available in pack sizes of:
Zdravilo Extavia je na voljo v pakiranjih, ki vsebujejo:
Extavia is given by an injection under the skin.
Zdravilo Extavia se injicira pod kožo.
Extavia is injected under the skin so any food or drink you consume is not thought to have any effect on Extavia.
Zdravilo Extavia se injicira pod kožo, zato vpliva hrane ali pijače ni mogoče pričakovati.
Extavia is used to treat adult patients who have multiple sclerosis (MS).
Zdravilo Extavia je namenjeno za zdravljenje odraslih bolnikov z multiplo sklerozo.
Extavia must not be used in patients who are currently suffering from severe depression and/or have thoughts of suicide.
Zdravila Extavia prav tako ne smejo uporabljati bolniki, ki trpijo za težko depresijo in/ali imajo samomorilne misli.
Extavia must not be used in patients who have decompensated liver disease (when the liver does not function normally).
N smejo ga uporabljati bolniki z dekompenzirano boleznijo jeter (kadar jetra ne delujejo normalno).
Extavia must not be used in people who have a history of hypersensitivity (allergy) to natural or recombinant interferon beta, human albumin or any of the other ingredients.
Zdravila Extavia ne smejo uporabljati osebe, ki so bile v preteklosti preobčutljive za (alergične na) naravni ali rekombinantni interferon beta, humani albumin ali katero koli drugo sestavino zdravila.
Extavia should be used with caution with:
Zdravilo Extavia je treba uporabljati previdno z:
Extavia therapy should not be started if you are pregnant (see also “Do not use Extavia”).
Če ste noseči, ne smete začeti zdravljenja z zdravilom Extavia (glejte tudi Ne uporabljajte zdravila Extavia).
Extavia treatment must not be started during pregnancy.
Zdravljenje z zdravilom Extavia se ne sme uvesti med nosečnostjo.
Extavia treatment should be started by a doctor who has experience in the treatment of MS.
Zdravljenje z zdravilom Extavia mora uvesti zdravnik, ki ima izkušnje z zdravljenjem multiple skleroze.
Extavia treatment should be stopped in patients who fail to respond.
Pri bolnikih, ki se ne odzivajo na zdravljenje z zdravilom Extavia, je treba zdravljenje prekiniti.
Extavia was studied over a two year period in 338 patients with relapsing remitting MS who were able to walk unaided, where its effectiveness was compared with placebo (a dummy treatment).
Zdravilo Extavia so proučevali dve leti pri 338 bolnikih z recidivno-remitentno multiplo sklerozo, sposobnih hoje brez pomoči, pri čemer so učinkovitost zdravila primerjali z učinkovitostjo placeba (zdravila brez zdravilne učinkovine).
Extavia with food and drink
Zdravilo Extavia skupaj s hrano in pijačo
Extemporaneous formulation
Sprotna (ex-tempore) izdelava
Extend heart rate monitoring for at least overnight in a medical facility and until resolution of findings in patients requiring pharmacological intervention during monitoring at treatment initiation/re-initiation.
Spremljanje srčne frekvence v zdravstveni ustanovi je treba podaljšati najmanj preko noči in dokler ugotovljene motnje ne izzvenijo pri bolnikih, pri katerih je bilo treba v času spremljanja ob uvedbi oziroma ponovni uvedbi zdravljenja farmakološko ukrepati.
Extend heart rate monitoring for at least overnight in a medical facility and until resolution of findings in patients:
Spremljanje srčne frekvence v zdravstveni ustanovi je treba pri bolniku podaljšati najmanj preko noči in dokler ugotovljene motnje ne izzvenijo:
Extended and frequent
Priporočljiv
Extended and frequent monitoring for respiratory depression and other opiate-associated adverse reactions is recommended.
pojavljanja depresije dihanja in drugih z opiati povezanih neželenih učinkov.
Extended criteria donors were defined as deceased donors with at least one of the following: (1) donor age ≥ 60 years; (2) donor age ≥ 50 years and other donor comorbidities (≥ 2 of the following: stroke, hypertension, serum creatinine > 1.5 mg/dl); (3) donation after cardiac death or (4) anticipated cold ischemia time of ≥ 24 hours.
Razširjeni kriteriji darovani organ opredeljujejo kot organ umrlega darovalca, pri katerem je izpolnjen vsaj eden od naslednjih kriterijev: (1) starost darovalca ≥ 60 let; (2) starost darovalca ≥ 50 let in prisotnost drugih sočasnih bolezni (dve ali več od naslednjih: možganska kap, hipertenzija, vrednost serumskega kreatinina > 1,5 mg/dl); (3) darovanje po srčni smrti ali (4) pričakovani čas hladne ishemije ≥ 24 ur.
Extending the infusion time of doripenem to 4 hours maximises the % T>MIC for a given dose and is the basis for the option to administer 4-hour infusions in patients with nosocomial pneumonia including ventilator-associated pneumonia.
Ta ugotovitev je služila kot osnova za možnost dajanja 4-urnih infuzij bolnikom z bolnišnično pljučnico, vključno s pljučnico, povezano z uporabo respiratorja.
Extension of treatment beyond 12 months should be done on an individual patient basis as experience up to 24 months is limited (see section 5.1).
Podaljšanje zdravljenja na več kot 12 mesecev je treba pretehtati pri vsakem bolniku, ker je izkušenj z zdravljenjem, daljšim od 24 mesecev malo (glejte poglavje 5.1).
Extension Study (N=13) ZLB05_006CR
Podaljšana študija (N = 13) ZLB05_006CR
Extensions of both studies confirmed the long-term benefit of Signifor in patients with acromegaly.
V podaljšani fazi obeh študij so bile potrjene dolgoročne koristi zdravila Signifor pri bolnikih z akromegalijo.
Extensive dose-range and adjustment studies with the medicinal product in normal and special populations have not been performed.
Študije prekomernih odmerkov in prilagoditve z zdravilom pri normalnih in posebnih populacijah niso bile izvedene.
Extensive limb swelling at the injection site, frequently associated with erythema, sometimes involving the adjacent joint or swelling of the entire injected limb
obsežna oteklina okončine na mestu injiciranja, ki včasih zajame sosednji sklep in je pogosto povezana z eritemom ali oteklina celotne okončine v katero je bilo injicirano cepivo
Extensive limb swelling: Large injection-site reactions (>50 mm), including extensive limb swelling from the injection site beyond one or both joints, have been reported in children.
Obsežno otekanje udov: Pri otrocih poročajo o večjih reakcijah na mestu injiciranja (>50 mm), vključno z obširnim otekanjem udov od mesta injiciranja prek enega ali obeh sklepov.
Extensive limb swelling†
obsežno otekanje udov
Extensive metabolism: CYP2C19*1/*1 74
Obsežna prenova: CYP2C19*1/*1 74
Extensive swelling of the vaccinated limb from the injection site beyond one or both joints, has been reported in children.
Pri otrocih so poročali o obsežnem otekanju cepljenih udov od mesta injiciranja prek enega ali obeh sklepov.
extensively metabolised by CYP3A.
obsežno presnavljajo s CYP3A.
Extent of liver fibrosis
Obseg jetrne fibroze
External beam
Zunanje obsevanje za
External genital and perianal warts (condylomata acuminata) in adults.
zunanjih bradavic na spolovilu in v okolici zadnjične odprtine (condylomata acuminata) pri odraslih bolnikih
External genital lesions
lezije na zunanjih spolovilih
External HPV 6-, 11-, 16-, or 18-related Genital Lesions***
Lezije na zunanjih spolovilih, povezane s HPV 6, 11, 16 ali 18
Extra large dogs (40 to 60 kg)
Zelo veliki psi (40 do 60 kg)
extra pulmonary tuberculosis (e.g. central nervous system, bone) infections due to Mycobacterial species other than those of the M. tuberculosis complex latent infection with M. tuberculosis
zunajpljučne tuberkuloze (npr. osrednji živčni sistem, kosti) okužbe z vrsto mikobakterije, razen s sklopom M. tuberculosis latentne okužbe z M. tuberculosis
extra-pulmonary tuberculosis (e.g. central nervous system, bone) infections due to mycobacterial species other than Mycobacterium tuberculosis latent infection with Mycobacterium tuberculosis
ekstrapulmonalne tuberkuloze (na primer tuberkuloze centralnega živčevja, kosti) okužb z drugimi mikobakterijami (razen Mycobacterium tuberculosis) latentne okužbe z bakterijo Mycobacterium tuberculosis.
Extracellular binding of the toxin to specific acceptors on motor nerve terminals
zunajcelična vezava toksina na specifične akceptorje na končičih motoričnih nevronov;
Extrahepatic metabolism by CYP3A4 in intestine, CYP1A1 in lung, and 1B1 in tumour tissue potentially contribute to the metabolic clearance of erlotinib.
Presnova zunaj jeter poteka s CYP3A4 v črevesju, CYP1A1 v pljučih, CYP1B1 v tumorskem tkivu ter tako lahko prispeva k presnovnemu očistku erlotiniba.
Extrahepatic metabolism by CYP3A4 in intestine, CYP1A1 in lung, and CYP1B1 in tumour tissue also potentially contribute to the metabolic clearance of erlotinib.
Presnova erlotiniba zunaj jeter poteka s CYP3A4 v črevesju, CYP1A1 v pljučih in CYP1B1 v tumorskih tkivih ter lahko prispeva k presnovnemu očistku erlotiniba.
Extrapancreatic effects include an improvement in insulin sensitivity of peripheral tissue and a reduction in hepatic uptake of insulin.
Med zunajpankreatičnimi učinki so izboljšanje občutljivosti za insulin v perifernih tkivih in zmanjšanje jetrnega privzema insulina.
Extrapyramidal reactions
ekstrapiramidne reakcije,
Extrapyramidal symptoms
ekstrapiramidni simptomi
Extrapyramidal symptoms
ekstrapiramidnih simptomih,
Extrapyramidal symptoms (EPS) included a pooled analysis of the following terms: parkinsonism (includes extrapyramidal disorder, extrapyramidal symptoms, on and off phenomenon, Parkinson’s disease, parkinsonian crisis, salivary hypersecretion, musculoskeletal stiffness, parkinsonism, drooling, cogwheel rigidity, bradykinesia, hypokinesia, masked facies, muscle tightness, akinesia, nuchal rigidity, muscle rigidity, parkinsonian gait, glabellar reflex abnormal, and parkinsonian rest tremor), akathisia (includes akathisia, restlessness, hyperkinesia, and restless leg syndrome), dyskinesia (dyskinesia, chorea, movement disorder, muscle twitching, choreoathetosis, athetosis, and myoclonus), dystonia (includes dystonia, cervical spasm, emprosthotonus, oculogyric crisis, oromandibular dystonia, risus sardonicus, tetany, hypertonia, torticollis, muscle contractions involuntary, muscle contracture, blepharospasm, oculogyration, tongue paralysis, facial spasm, laryngospasm, myotonia, opisthotonus, oropharyngeal spasm, pleurothotonus, tongue spasm, and trismus), and tremor.
EPS so vključevali združeno analizo naslednjih terminov: parkinsonizem (vključuje ekstrapiramidne motnje, ekstrapiramidne simptome, fenomen vklop-izklop, Parkinsonovo bolezen, parkinsonsko krizo, prekomerno izločanje sline, okorelost mišic in skeleta, parkinsonizem, slinjenje, rigidnost zobatega kolesa, bradikinezijo, hipokinezijo, obraz maske, mišično napetost, akinezijo, okorel vrat, rigidnost mišic, parkinsonsko držo in nenormalni grabelarni refleks, parkinsonski tremor v mirovanju); akatizija (vključuje akatizijo, nemir, hiperkinezijo in sindrom nemirnih nog); diskinezija (vključuje diskinezijo, horeo, motnje gibanja, trzanje mišic, horeoatetozo, atetozo, in mioklonus); distonija (vključuje distonijo, spazem vratnih mišic, emprostotonus, okulogirno krizo, oromandibularno distonijo, risus sardonicus, tetanijo, hipertonijo, tortikolis, nenadzorovano krčenje mišic, kontrakture mišic, blefarospazem, okulogiracijo, paralizo jezika, obrazne krče, laringospazem, miotonijo, opistotonus, orofaringealne krče, plevrototonus, krč jezika in trizmus) ter tremor.
Extrapyramidal symptoms (EPS): In the short-term placebo controlled studies, the incidence of reported events related to EPS, excluding akathisia and restlessness, was 13.5% for lurasidone-treated subjects versus 5.8% for placebo-treated subjects.
Ekstrapiramidni simptomi: V kratkotrajnih, s placebom nadzorovanih študijah, je pojavnost sporočenih dogodkov, povezanih z ekstrapiramidnimi simptomi, razen akatizije in nemira, pri osebah, ki so se zdravile z lurasidonom znašala 13,5 %, pri osebah, ki so prejemale placebo pa 5,8 %.
Extrapyramidal symptoms (including worsening of
ekstrapiramidni simptomi (vključno s poslabšanjem
Extrapyramidal symptoms (including worsening of Parkinson’s disease)
ekstrapiramidni simptomi (vključno s poslabšanjem Parkinsonove bolezni)
Extrapyramidal syndrome
ekstrapiramidni sindrom
Extrasystoles Bradycardia
ektrasistole bradikardija
Extrauterine pregnancy in the previous 3 months
zunajmaternična nosečnost v zadnjih 3 mesecih
extravasation (leakage of the infusion to the surrounding tissue): pain, burning sensation, stinging or another reaction at the infusion site during administration.
ekstravazacija (iztekanje infuzije v okoliško tkivo): bolečina, pekoč občutek, zbadanje ali druge reakcije na mestu infundiranja med dajanjem infuzije.
Extravasation and Tissue necrosis: During post-marketing surveillance, a few cases of trabectedin extravasation with subsequent tissue necrosis requiring debridement have been reported (see section 4.4).
Ekstravazacija in nekroza tkiva: V okviru nadzora v obdobju trženja so poročali o nekaj primerih ekstravazacije trabektedina, ki ji je sledila nekroza tkiva, zaradi katere je bila potrebna odstranitev odmrlega tkiva (glejte poglavje 4.4.).
Extravasation should be managed by local standard practice.
Ekstravazacijo je treba obravnavati v skladu z uveljavljeno lokalno prakso.
Extravasation*, application site inflammation*.
Ekstravazacija*, vnetje mesta aplikacije
Extremadura 3, 09400 Aranda De Duero, Burgos, Spain
Extremadura 3, 09400 Aranda De Duero, Burgos, Španija
Extremadura, 3 Pol.
Extremadura 3 Pol.
Extreme care must be taken to avoid pregnancy in female patients or in partners of male patients taking Viraferon in combination with ribavirin.
previdnost v izogib nosečnosti pri bolnicah ter tudi pri partnerkah bolnikov, ki jemljejo zdravilo Viraferon v kombinaciji z ribavirinom.
Extreme care must be taken to avoid pregnancy in female patients.
Izjemno skrbno moramo paziti, da preprečimo zanositev bolnice med zdravljenjem.
Extreme care must be taken to avoid pregnancy in partners of male patients taking Ribavirin Teva Pharma B.V. (see sections 4.3, 4.4 and 5.3).
Izjemno skrbno moramo paziti, da preprečimo zanositev pri partnerkah moških bolnikov, ki jemljejo zdravilo Ribavirin Teva Phama B.V. (glejte poglavja 4.3, 4.4 in 5.3).
Extreme care should, therefore, be taken when using Econor in pigs of Scandinavian origin.
Zato je pri uporabi zdravila Econor pri pasmah skandinavskega porekla potrebna izjemna previdnost.
Extreme caution must be exercised if caffeine citrate is used in newborns with seizure disorders.
Pri novorojenčkih z epileptičnimi napadi je potrebna izjemna previdnost pri dajanju kofeinijevega citrata.
Extreme caution must be taken to avoid pregnancy in female patients and female partners of male patients when Exviera is used with ribavirin.
Če je zdravilo Exviera uporabljeno z ribavirinom, je potrebna skrajna previdnost, da bi preprečili nosečnost bolnic in partnerk bolnikov.
Extreme caution must be taken to avoid pregnancy in female patients and female partners of male patients when Viekirax is taken in combination with ribavirin.
Če je zdravilo Viekirax uporabljeno v kombinaciji z ribavirinom, je potrebna skrajna previdnost, da bi preprečili nosečnost bolnic in partnerk bolnikov.
Extreme caution should be used when considering the administration of Luminity to patients with unstable cardiopulmonary status, for example: unstable angina, acute myocardial infarction, severe ventricular arrhythmias, severe heart failure (NYHA IV) or respiratory failure.
Pri bolnikih z nestabilnim kardiopulmonalnim stanjem je treba zdravilo Luminity uporabljati izjemno previdno, npr. pri bolnikih z nestabilno angino pektoris, akutnim miokardnim infarktom, s hudo ventrikularno aritmijo, hudim srčnim popuščanjem (NYHA IV) ali z respiratorno odpovedjo.
extreme difficulty in breathing, fluid accumulation in the lungs, inflammation of the lungs, hay fever
hude težave pri dihanju, kopičenje tekočine v pljučih, vnetje pljuč, seneni nahod
extreme tiredness (asthenia) increase in blood cholesterol seen in blood tests, increase in blood fats (triglycerides) seen in blood tests.
izjemna utrujenost (astenija), povišanje ravni holesterola v krvi pri krvnih preiskavah, povišanje maščob (trigliceridov) v krvi pri krvnih preiskavah.
extreme tiredness (fatigue)
huda utrujenost
extreme tiredness (fatigue); fever or high temperature (pyrexia); lack or loss of strength (asthenia); accumulation of fluid in the extremities (oedema peripheral);
krajna izčrpanost (utrujenost), zvišana ali visoka telesna temperatura (pireksija), pomanjkanje ali izguba moči (astenija), kopičenje tekočine v okončinah (periferni edemi),
Extreme tiredness, loss of strength.
huda utrujenost, izguba moči
Extreme tiredness.
hudo utrujenost,
extreme weakness, anxiety, or shortness of breath;
krajna šibkost, tesnoba ali kratka sapa;
extreme weakness, anxiety, or shortness of breath; rapid or irregular heartbeats.
izjemna šibkost, tesnoba ali kratka sapa; hiter ali nepravilen srčni utrip
extreme weakness, anxiety, or shortness of breath; rapid or irregular heartbeats.
izjemna šibkost, tesnoba ali kratka sapa; hiter ali nepravilen srčni utrip.
extreme weakness, anxiety, or shortness of breath; rapid or irregular heartbeats.
krajna šibkost, tesnoba ali kratka sapa, hitro ali neredno bitje srca.
Extremely rarely, thrombosis has been reported to occur in CHC users in other blood vessels, e.g. hepatic, mesenteric, renal, or retinal veins and arteries.
Pri uporabnicah CHC so izredno redko poročali o nastanku tromboze tudi v drugih krvnih žilah, npr. v jetrnih, mezenteričnih, ledvičnih, mrežničnih venah in arterijah.
Extremely rarely, thrombosis has been reported to occur in CHC users in other blood vessels, e.g. hepatic, mesenteric, renal, or retinal veins and arteries.
Pri uporabnicah KPK so izredno redko poročali o nastanku tromboze tudi v drugih krvnih žilah, npr. v jetrnih, mezenteričnih, ledvičnih, mrežničnih venah in arterijah.